ResMed Inc. (ASX: RMD)
Market Cap | 55.66B |
Revenue (ttm) | 6.93B |
Net Income (ttm) | 1.61B |
Shares Out | n/a |
EPS (ttm) | 10.87 |
PE Ratio | 34.67 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | Nov 6, 2024 |
Volume | 1,056,251 |
Open | 38.15 |
Previous Close | 38.15 |
Day's Range | 37.73 - 38.15 |
52-Week Range | 24.27 - 39.13 |
Beta | 0.69 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Jan 23, 2025 |
About ResMed
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on de... [Read more]
Financial Performance
In 2024, ResMed's revenue was $4.69 billion, an increase of 10.95% compared to the previous year's $4.22 billion. Earnings were $1.02 billion, an increase of 13.75%.
Financial numbers in USD Financial StatementsNews
My Top 15 High-Growth Dividend Stocks For December 2024
The SPDR S&P 500 ETF Trust posted a strong gain of 5.96% in November, resuming its strong run in 2024. The Top 15 dividend growth stocks for December 2024 offer an average dividend yield of 1.2% and a...
Insider Transaction: Michael J Farrell Sells $499K Worth Of ResMed Shares
It was reported on November 27, that Michael J Farrell , Chief Executive Officer at ResMed (NYSE: RMD) executed a significant insider sell, according to an SEC filing. What Happened: Farrell's decisi...
Downgrading ResMed Inc. Because It's Doing Well
ResMed: Solid Execution, Pricey Valuation
Insider Sell: Justin Leong Sells 6,160 Shares of ResMed Inc (RMD)
Insider Sell: Justin Leong Sells 6,160 Shares of ResMed Inc (RMD)
ResMed Inc (RMD)'s Winning Formula: Financial Metrics and Competitive Strengths
ResMed Inc (RMD)'s Winning Formula: Financial Metrics and Competitive Strengths
ResMed expands Singapore operations to address obstructive sleep conditions
Mick Farrell, CEO of medical equipment maker ResMed, says the company is pouring "tens of millions of dollars" into expanding its Singapore operations as it aims to help 500 million people sleep bette...
ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Year
ResMed shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.
Insider Sale: Director Witte De Sells Shares of ResMed Inc (RMD)
Insider Sale: Director Witte De Sells Shares of ResMed Inc (RMD)
Exploring the $188 Billion Opportunity: Why AI is Set to Transform Global Healthcare by 2030
Issued on behalf of Avant Technologies Inc. USA News Group News Commentary VANCOUVER, BC , Nov. 12, 2024 /PRNewswire/ -- Recently the World Economic Forum released a report that highlights AI's potent...
Insider Sale: Director Peter Farrell Sells Shares of ResMed Inc (RMD)
Insider Sale: Director Peter Farrell Sells Shares of ResMed Inc (RMD)
ResMed Announces Participation in the UBS Global Healthcare Conference
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will particip...
My Top 15 High-Growth Dividend Stocks For November 2024
The SPDR S&P 500 ETF Trust posted a loss of 0.89% in October, putting a pause on its strong run in 2024. The Top 15 dividend growth stocks for November 2024 offer an average dividend yield of 1.24% an...
ResMed CEO On Earnings, Sleep Apnea
ResMed (RMD) CEO Mick Farrell joins Morning Trade Live to discuss the company's latest earnings beat. ResMed primarily focuses on sleep apnea and COPD.
P/E Ratio Insights for ResMed
In the current market session, ResMed Inc. (NYSE: RMD) stock price is at $249.21, after a 2.68% decrease. However, over the past month, the company's stock increased by 4.38% , and in the past year, ...
Sleep Apnea Device Maker ResMed Is A Durable MedTech, With Positive Fundamentals, Says Analyst
On Thursday, ResMed Inc (NYSE: RMD) reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus of $2.04 . The company reported sales of $1.224 billion, up 11%, beating...
Sleep Apnea Device Maker ResMed Is A Durable MedTech, With Positive Fundamentals, Says Analyst
On Thursday, ResMed Inc RMD reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus of $2.04.
ResMed declares $0.53 dividend
ResMed Inc. (RMD) Q1 2025 Earnings Call Transcript
ResMed Inc. (NYSE:RMD) Q1 2025 Earnings Conference Call October 24, 2024 4:30 PM ETCompany ParticipantsAmy Wakeham - Chief Investor Relations OfficerMichael...
ResMed rises 5% on Q3 beats
ResMed (RMD) reports strong Q3 financial results, with non-GAAP net income up 35% and gross margin improving by 320 bps. Read more here.
ResMed beats quarterly profit estimates on strong demand for its sleep apnea devices
ResMed beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its devices used for sleep apnea treatment.
ASX 200 LIVE: Shares gain; WiseTech has best day in two months; Qantas upbeat on domestic travel; ACCC clears Accolade-Pernod deal; Metcash flags cost-cutting, ResMed ups revenue.
Shares gain; WiseTech has best day in two months; Qantas upbeat on domestic travel; ACCC clears Accolade-Pernod deal; Metcash flags cost-cutting, ResMed ups revenue. Follow updates here.
Obesity Drugs-Tied ResMed Edges Higher On Quarterly Beat
ResMed stock rose Thursday after beating quarterly expectations, shrugging off worries that weight-loss drugs would hammer its topline.
A Peek at ResMed's Future Earnings
ResMed (NYSE: RMD) is set to give its latest quarterly earnings report on Thursday, 2024-10-24. Here's what investors need to know before the announcement. Analysts estimate that ResMed will report a...
Brendan Caldwell 's Top Picks: ResMed, Carrier Global Corp, and Equifax
Brendan Caldwell, president and CEO of Caldwell Investment Management, discusses his top picks: ResMed, Carrier Global Corp, and Equifax.